| P2093 | author name string | Matthew R Smith | |
| | Philip J Saylor | |
| | Richard J Lee | |
| P2860 | cites work | Biology of RANK, RANKL, and osteoprotegerin | Q21195419 |
| | Metabolic complications of androgen deprivation therapy for prostate cancer | Q24616159 |
| | Cancer statistics, 2009 | Q29547625 |
| | Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 |
| | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 |
| | Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. | Q31831133 |
| | Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases | Q62392239 |
| | Morphometric evidence for bone resorption and replacement in prostate cancer | Q67946292 |
| | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group | Q71890854 |
| | Correlation between bone metabolic markers and bone scan in prostatic cancer | Q71975817 |
| | Osteoblast function and osteomalacia in metastatic prostate cancer | Q72930512 |
| | Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making | Q73290328 |
| | Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline | Q74327863 |
| | Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer | Q74494160 |
| | Reduction in new metastases in breast cancer with adjuvant clodronate treatment | Q74837359 |
| | Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial | Q79984455 |
| | Risk of fracture after androgen deprivation for prostate cancer | Q81264327 |
| | Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer | Q83895054 |
| | Osteoporosis in men. | Q33752465 |
| | Mechanisms of bone metastasis | Q33977526 |
| | Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer | Q33977543 |
| | A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | Q34152748 |
| | Osteoclastic bone resorption by a polarized vacuolar proton pump | Q34441726 |
| | Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 |
| | Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. | Q34617892 |
| | Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer | Q34617931 |
| | Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer | Q34617956 |
| | Endocrine therapy plus zoledronic acid in premenopausal breast cancer. | Q34943802 |
| | Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study | Q34960850 |
| | Clinical development of anti-RANKL therapy | Q35901092 |
| | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 |
| | Targeting bone metastasis in prostate cancer with endothelin receptor antagonists | Q36633818 |
| | Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials | Q37357660 |
| | Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 |
| | Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells | Q40268466 |
| | Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model | Q40538169 |
| | World-wide projections for hip fracture | Q40909953 |
| | Overview of bisphosphonates | Q41637516 |
| | Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial | Q43514162 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer | Q43749401 |
| | The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study | Q43824306 |
| | Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer | Q44083704 |
| | Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model | Q44164597 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer | Q44456773 |
| | Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group | Q44547450 |
| | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain | Q44567816 |
| | A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). | Q44571738 |
| | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial | Q44611376 |
| | Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer | Q44634009 |
| | Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer | Q44918129 |
| | Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial | Q45006027 |
| | Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer | Q45100385 |
| | Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors | Q45211867 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer | Q46463184 |
| | Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer | Q46890119 |
| | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 |
| | Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873) | Q57253156 |
| | Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma | Q57905146 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 29-36 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Clinical Genitourinary Cancer | Q332266 |
| P1476 | title | Contemporary therapeutic approaches targeting bone complications in prostate cancer | |
| P478 | volume | 8 | |